Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis

被引:0
作者
Kai-Wen Xiao
Liang Zhou
Qing He
Xiao-Shuai Gao
Guo Chen
Yu-Cheng Ma
Hong Li
Kun-Jie Wang
机构
[1] Sichuan University,Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital
来源
Lasers in Medical Science | 2019年 / 34卷
关键词
Thulium laser; Holmium laser; Enucleation; Safety; Efficacy; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
To evaluate the clinical efficacy and safety of thulium laser vapoenucleation/enucleation of the prostate (ThuEP) versus holmium laser enucleation of the prostate (HoLEP) in the management of benign prostatic hyperplasia (BPH). A systematic literature search was performed using PubMed, Embase, and Web of Science to identify eligible studies published before July 2018. Meta-analysis of extracted data was performed with RevMan version 5.3. We chose the fixed- or random-effect model to fit the pooled heterogeneity. Five eligible studies including two randomized controlled trials (RCTs) and three non-RCTs involving 1010 patients were enrolled in our meta-analysis. ThuEP provided less enucleation time when compared with HoLEP (WMD = − 7.73, 95% CI − 14.39–1.07, P = 0.02). During the 1st, 6th, and 12th months of postoperative follow-ups, statistically significant differences were found in Qmax (WMD = 2.05, 95% CI 0.52~3.58) and PVR (WMD = − 6.50, 95% CI − 7.35~− 5.66, P < 0.001) in the 1st month after the operation, also in IPSS (IPSS: WMD = − 1.29, 95% CI − 2.39~− 0.19, P = 0.02) in the 12th month after the operation. As regards other perioperative, postoperative parameters, and complication rates, we found no significant difference. Both ThuEP and HoLEP provided satisfactory micturition improvement with low morbidity after the 1st and 6th months of the operation. However, ThuEP showed higher enucleation efficacy and less intraoperative blood loss and may get a better outcome as compared to the HoLEP group in the early postoperative period with regard to Qmax/PVR and IPSS after the 1st and 12th months of the operation respectively.
引用
收藏
页码:815 / 826
页数:11
相关论文
共 203 条
[1]  
Mcvary KT(2011)Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 1793-1803
[2]  
Roehrborn CG(2002)The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 167-178
[3]  
Avins AL(2015)EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Eur Urol 67 1099-1109
[4]  
Barry MJ(2008)Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients J Urol 180 246-249
[5]  
Bruskewitz RC(2006)Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention Eur Urol 50 969-979
[6]  
Donnell RF(2014)Long-term outcomes of 80-watt KTP and 120-watt HPS GreenLight photoselective vaporization of the prostate.%A Broggi E Urologia internationalis 93 229-236
[7]  
Foster HE(1998)Holmium laser prostatectomy: a technique in evolution Curr Opin Urol 8 11-15
[8]  
Gonzalez CM(2015)A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update Eur Urol 67 1066-1096
[9]  
Kaplan SA(2014)Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis PLoS One 9 e101615-611
[10]  
Penson DF(2013)Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials J Endourol 27 604-56